Acyclovir Reaches Clinical Trial

Excerpt

The report in this issue by Wade and colleagues (1), from the University of Washington and the Fred Hutchinson Cancer Research Center in Seattle, and the Burroughs Wellcome Co. , describes patients who developed mucocutaneous herpes simplex virus infections after bone marrow transplantation and were successfully treated with acyclovir (acycloguanosine; 9-(2-hydroxyethoxymethyl) guanine; zovirax, acyclovir). A second paper, by Strauss and colleagues (2), from the National Institute of Allergy and Infectious Diseases in Bethesda and the Burroughs Wellcome Co., records a similar accomplishment along with proplylaxis of recurrent mucocutaneous herpes simplex virus infections in five severely immunocompromised patients with nucleoside phosphroylase